Serum tissue polypeptide specific antigen (TPS) in breast cancer patients: comparison with CA 15.3 and CEA.
Pre-treatment TPS serum levels from patients with Stage IV breast cancer (n = 66) (1386.0 +/- 3504.5) were significantly higher (p < 0.0001), than normal controls (n = 47), (75.5 +/- 111.5 U/L), benign breast disease patients (n = 84) (58.5 +/ 57.1 U/L), and breast cancer patients with Stage I/II (n = 79) (52.7 +I- 49.5U/L) or Stage III disease (n = 57) (166.7 +/- 218.8). Analysis of sequentially obtained samples from Stage IV patients during endocrine treatment showed TPS alone or in combination with CEA and CA 15.3 was less accurate in predicting response than the combination of CEA with CA 15.3. In this study TPS did not usefully add to the established marker combination of CEA and CA 15.3.
Willsher
P C
PC
Professorial Department of Surgery, City Hospital, Nottingham, U.K.
Beaver
J
J
Blamey
R W
RW
Robertson
J F
JF
D014408:Biomarkers, Tumor / Q000097:blood*; D001943:Breast Neoplasms / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood*; D005260:Female; D006801:Humans; D018396:Mucin-1 / Q000097:blood*; D010455:Peptides / Q000097:blood*
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D018396:Mucin-1; D010455:Peptides; C089984:tissue polypeptide specific antigen